A retrospective observational study assessing the therapeutic management of relapsing-remitting multiple sclerosis in France
Latest Information Update: 14 Dec 2021
At a glance
- Drugs Dimethyl fumarate (Primary) ; Fingolimod (Primary) ; Glatiramer acetate (Primary) ; Interferon beta-1a (Primary) ; Interferon beta-1b (Primary) ; Natalizumab (Primary) ; Ocrelizumab (Primary) ; Peginterferon alfa-2a (Primary) ; Peginterferon beta-1a (Primary) ; Rituximab (Primary) ; Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 14 Dec 2021 New trial record
- 15 Oct 2021 Results presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis